Loading...
Market
Will the FDA approve Wainzua by mid-2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official website or press release from Ionis Pharmaceuticals or AstraZeneca
Story
CHMP Recommends Approval of Ionis and AstraZeneca's Wainzua for Rare Polyneuropathy
Oct 21, 2024, 06:10 AM
The Committee for Medicinal Products for Human Use (CHMP) in the EU has recommended the approval of Wainzua (eplontersen), a treatment developed by Ionis Pharmaceuticals and AstraZeneca, for adult patients with stage 1 or stage 2 polyneuropathy associated with hereditary transthyretin-mediated amyloidosis. This recommendation marks a significant step forward for patients suffering from this rare condition.
View original story
Similar markets
Yes • 50%
No • 50%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
Approval • 33%
Rejection • 33%
Request for more data • 34%